Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06969807RecruitingPhase 2
Stem cells for diabetic kidney disease
This trial tests whether a type of stem cell called mesenchymal stromal cells (Amimestrocel) can help people with diabetic kidney disease. It aims to see if the treatment is safe and can improve kidney function.
Beijing, Beijing MunicipalityAges 18–80 - NCT06970145RecruitingPhase 1/Phase 2
Anlotinib for recurrent craniopharyngioma
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
Guangzhou, GuangdongAges 18–75 - NCT06964620RecruitingEarly Phase 1
Sanggua tablets for early type 2 diabetes or prediabetes
This trial tests whether an herbal medicine called Sanggua tablets can help control blood sugar in people with prediabetes or mild type 2 diabetes who are not yet taking diabetes pills. If you have slightly high blood sugar but don't need medication yet, this study may help you manage it naturally.
Wuhan, HubeiAges 18–70 - NCT06754644RecruitingPhase 3
Study of QL2107 plus chemo vs. Keytruda for advanced lung cancer
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
Jinan, ShandongAges 18–75 - NCT06953726RecruitingPhase 4
Comparing apixaban and rivaroxaban for atrial fibrillation
This study compares two blood thinners, apixaban and rivaroxaban, to see which is safer and works better for veterans with atrial fibrillation (irregular heartbeat). If you're already taking one of these, the study will assign you to one of them.
West Los Angeles, CaliforniaAges 22 years+ - NCT06952842RecruitingPhase 1/Phase 2
Gene therapy trial for retinitis pigmentosa with RHO mutation
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06962098RecruitingPhase 2
Study of isuzinaxib for diabetic kidney disease
This trial tests an investigational drug called isuzinaxib (APX-115) for people with type 2 diabetes and diabetic kidney disease (DKD). The goal is to see if it can help protect kidney function. Participants must have stable kidney lab values and be on certain blood pressure or diabetes medications.
Ansan-siAges 19 years+ - NCT06959082RecruitingPhase 2
Testing an experimental drug with chemoradiation for head and neck cancer
This trial tests an experimental drug called VS-101 combined with standard radiation and chemotherapy for people with advanced head and neck cancer that hasn't been surgically removed. The goal is to see if adding this drug helps the treatment work better while keeping side effects manageable.
New Haven, ConnecticutAges 18 years+ - NCT06956014RecruitingPhase 3
Testing a new drug for chronic back and leg pain
This trial tests an investigational drug called VER-01 for people with long-term pain from a pinched nerve in the lower back. It aims to see if the drug safely reduces pain and improves daily life.
Katy, TexasAges 18 years+ - NCT06960018Recruiting
Ennovate minimally invasive spinal screw placement study
This study tests a new, less invasive method for placing screws in the cervical spine (upper back and neck). It is designed for patients who need spinal stabilization after injury or degeneration.
AachenAges 18 years+ - NCT06953323RecruitingPhase 1/Phase 2
Study of WJB001 combination for advanced solid tumors
This trial tests a new combination drug for people with advanced solid tumors, especially certain gynecologic cancers, that have not responded to standard treatments. The treatment aims to target a specific genetic marker (CCNE1) found in the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06959030Recruiting
Study of Henagliflozin for Type 2 Diabetes
This study tests how safe and effective the diabetes medication henagliflozin is for Chinese patients with type 2 diabetes. It is an observational study, meaning you will continue your regular care while researchers watch your progress.
Beihai, GuangxiAges 18–80 - NCT06957093Recruiting
AI‐assisted diabetes care vs standard management
This study tests whether an AI‐powered digital health platform can help people with type 2 diabetes better manage their blood sugar. If you use a smartphone and have had diabetes for at least a year, this may be a convenient way to receive extra support.
Changchun, JilinAges 18–75 - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT06954740RecruitingPhase 2
Stem cell treatment for acute kidney injury
This study tests a special type of stem cell treatment called mesenchymal stromal cells (Amimestrocel) for patients with acute kidney injury. The goal is to see if this treatment can help kidneys recover better than standard care.
Beijing, Beijing MunicipalityAges 18–75 - NCT05545605Recruiting
Sodium oligomannate to prevent thinking problems after stroke
This trial tests whether sodium oligomannate can help prevent or lessen memory and thinking problems that can happen after a first stroke. It may help people who are recently hospitalized for ischemic stroke and have mild cognitive decline risk.
Guangzhou, BaiyunAges 18–80 - NCT06950242Enrolling by invitation
Laser balloon for narrowed brain arteries
This trial tests a new laser balloon catheter to widen narrowed arteries in the brain that cause stroke symptoms. It may help if you have a severely blocked artery and are healthy enough for the procedure.
Changzhou, JiangsuAges 18–80 - NCT06943729Recruiting
Testing a flow-diverter stent for brain aneurysms
This trial tests a flow-diverter stent (a small mesh tube) to treat brain aneurysms that are hard to close with standard methods. It may help if you have a wide-neck or other complex aneurysm that hasn't burst.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06946394RecruitingPhase 4
Switching anemia medicine for kidney disease patients
This trial tests a new medicine called pegmolesatide for people with chronic kidney disease and anemia. It compares switching to this new medicine versus staying on current treatments, to see if it is safe and works well.
Dalian, LiaoningAges 18–80 - NCT06948487Recruiting
Study of Fexuclu tablets for stomach inflammation (gastritis)
This study watches patients with acute or chronic gastritis who are already being prescribed the stomach medicine Fexuclu (fexuprazan). It collects information to see how well the medicine works and if it causes any side effects in everyday use.
SeoulAges 19–75 - NCT06944522RecruitingPhase 3
Cell therapy for Parkinson's symptoms
This study tests a new cell therapy called bemdaneprocel to see if it can reduce Parkinson's symptoms and “off” time. The treatment involves transplanting special cells into the brain to help replace lost dopamine-producing cells.
Scottsdale, ArizonaAges 45–75 - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+ - NCT06951711RecruitingPhase 3
KarXT for mania in bipolar I disorder
This study tests a new medication called KarXT to see if it helps calm manic episodes in people with bipolar I disorder. You would need to be in the hospital for a manic episode and stop other psychiatric medications temporarily.
Little Rock, ArkansasAges 18–65
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.